Research progress of extracellular vesicles in the treatment of ovarian diseases (Review)
- Authors:
- Yixin Zhang
- Jingyu Zhao
- Linqi Han
- Zihan Zhang
- Caiqin Wang
- Wei Long
- Kai Meng
- Xiaomei Wang
-
Affiliations: Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong 272067, P.R. China, College of Basic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China - Published online on: November 15, 2023 https://doi.org/10.3892/etm.2023.12303
- Article Number: 15
-
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Walbrecq G, Margue C, Behrmann I and Kreis S: Distinct cargos of small extracellular vesicles derived from hypoxic cells and their effect on cancer cells. Int J Mol Sci. 21(5071)2020.PubMed/NCBI View Article : Google Scholar | |
|
Zarà M, Guidetti GF, Camera M, Canobbio I, Amadio P, Torti M, Tremoli E and Barbieri SS: Biology and role of extracellular vesicles (EVs) in the pathogenesis of thrombosis. Int J Mol Sci. 20(2840)2019.PubMed/NCBI View Article : Google Scholar | |
|
Skotland T, Sagini K, Sandvig K and Llorente A: An emerging focus on lipids in extracellular vesicles. Adv Drug Deliv Rev. 159:308–321. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang W, Jo H, Park S, Kim H, Kim SI, Han Y, Lee J, Seol A, Kim J, Lee M, et al: Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer. Cancer Lett. 542(215735)2022.PubMed/NCBI View Article : Google Scholar | |
|
Kuhlmann JD, Chebouti I, Kimmig R, Buderath P, Reuter M, Puppel SH, Wimberger P and Kasimir-Bauer S: Extracellular vesicle-associated miRNAs in ovarian cancer-design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance. Clin Chem Lab Med. 57:1053–1062. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Koshiyama M, Matsumura N and Konishi I: Subtypes of ovarian cancer and ovarian cancer screening. Diagnostics (Basel). 7(12)2017.PubMed/NCBI View Article : Google Scholar | |
|
US Preventive Services Task Force. Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, et al: Screening for ovarian cancer: US preventive services task force recommendation statement. JAMA. 319:588–594. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Stewart C, Ralyea C and Lockwood S: Ovarian cancer: An integrated review. Semin Oncol Nurs. 35:151–156. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Coburn SB, Bray F, Sherman ME and Trabert B: International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 140:2451–2460. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kurman RJ: Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 24 (Suppl 10):x16–x21. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ and Shih IeM: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 95:484–486. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Karnezis AN, Cho KR, Gilks CB, Pearce CL and Huntsman DG: The disparate origins of ovarian cancers: Pathogenesis and prevention strategies. Nat Rev Cancer. 17:65–74. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Prat J: New insights into ovarian cancer pathology. Ann Oncol. 23 (Suppl 10):x111–x117. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Chan JK, Teoh D, Hu JM, Shin JY, Osann K and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 109:370–376. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST and Mok SC: Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: Cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 309:C444–C456. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 8:7018–7031. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kurnit KC, Fleming GF and Lengyel E: Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 137:108–121. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Woad KJ, Watkins WJ, Prendergast D and Shelling AN: The genetic basis of premature ovarian failure. Aust N Z J Obstet Gynaecol. 46:242–244. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Howell S and Shalet S: Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am. 27:927–943. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Ishizuka B: Current understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI). Front Endocrinol (Lausanne). 12(626924)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang F, Liu Y, Ni F, Jin J, Wu Y, Huang Y, Ye X, Shen X, Ying Y, Chen J, et al: BNC1 deficiency-triggered ferroptosis through the NF2-YAP pathway induces primary ovarian insufficiency. Nat Commun. 13(5871)2022.PubMed/NCBI View Article : Google Scholar | |
|
Domniz N and Meirow D: Premature ovarian insufficiency and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 60:42–55. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Goswami D and Conway GS: Premature ovarian failure. Hum Reprod Update. 11:391–410. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, Grymowicz M, Smolarczyk K, Kostrzak A, Smolarczyk R, Rudnicka E and Meczekalski B: Autoimmune diseases in patients with premature ovarian insufficiency-our current state of knowledge. Int J Mol Sci. 22(2594)2021.PubMed/NCBI View Article : Google Scholar | |
|
Sullivan SD, Sarrel PM and Nelson LM: Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 106:1588–1599. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zhang S, Zhu D, Mei X, Li Z, Li J, Xie M, Xie HJW, Wang S and Cheng K: Advances in biomaterials and regenerative medicine for primary ovarian insufficiency therapy. Bioact Mater. 6:1957–1972. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Sirmans SM and Pate KA: Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 6:1–13. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Meier RK: Polycystic ovary syndrome. Nurs Clin North Am. 53:407–420. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Wolf WM, Wattick RA, Kinkade ON and Olfert MD: Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 15(2589)2018.PubMed/NCBI View Article : Google Scholar | |
|
Louwers YV and Laven JSE: Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health. 14(2633494120911038)2020.PubMed/NCBI View Article : Google Scholar | |
|
Patel S: Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 182:27–36. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Pauli JM, Raja-Khan N, Wu X and Legro RS: Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med. 28:1445–1454. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Mitra S, Nayak PK and Agrawal S: Laparoscopic ovarian drilling: An alternative but not the ultimate in the management of polycystic ovary syndrome. J Nat Sci Biol Med. 6:40–48. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Tian W, Lei N, Zhou J, Chen M, Guo R, Qin B, Li Y and Chang L: Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death Dis. 13(64)2022.PubMed/NCBI View Article : Google Scholar | |
|
Ingenito F, Roscigno G, Affinito A, Nuzzo S, Scognamiglio I, Quintavalle C and Condorelli G: The Role of Exo-miRNAs in cancer: A focus on therapeutic and diagnostic applications. Int J Mol Sci. 20(4687)2019.PubMed/NCBI View Article : Google Scholar | |
|
Yang Y, Lang P, Zhang X, Wu X, Cao S, Zhao C, Shen R, Ling X, Yang Y and Zhang J: Molecular characterization of extracellular vesicles derived from follicular fluid of women with and without PCOS: Integrating analysis of differential miRNAs and proteins reveals vital molecules involving in PCOS. J Assist Reprod Genet. 40:537–552. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Park HS, Cetin E, Siblini H, Seok J, Alkelani H, Alkhrait S, Liakath Ali F, Mousaei Ghasroldasht M, Beckman A and Al-Hendy A: Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles to treat PCOS. Int J Mol Sci. 24(11151)2023.PubMed/NCBI View Article : Google Scholar | |
|
Geng Z, Guo H, Li Y, Liu Y and Zhao Y: Stem cell-derived extracellular vesicles: A novel and potential remedy for primary ovarian insufficiency. Front Cell Dev Biol. 11(1090997)2023.PubMed/NCBI View Article : Google Scholar | |
|
Fu YX, Ji J, Shan F, Li J and Hu R: Human mesenchymal stem cell treatment of premature ovarian failure: New challenges and opportunities. Stem Cell Res Ther. 12(161)2021.PubMed/NCBI View Article : Google Scholar | |
|
Dorayappan KDP, Wallbillich JJ, Cohn DE and Selvendiran K: The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol. 142:199–205. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Li SP, Lin ZX, Jiang XY and Yu XY: Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol Sin. 39:542–551. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Savina A, Furlán M, Vidal M and Colombo MI: Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 278:20083–20090. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernández-Delgado I, Torralba D, Moreno-Gonzalo O, Baldanta S, Enrich C, Guerra S and Sánchez-Madrid F: ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. Nat Commun. 7(13588)2016.PubMed/NCBI View Article : Google Scholar | |
|
Yang H, Fu H, Xu W and Zhang X: Exosomal non-coding RNAs: A promising cancer biomarker. Clin Chem Lab Med. 54:1871–1879. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Lin Y, Lu Y and Li X: Biological characteristics of exosomes and genetically engineered exosomes for the targeted delivery of therapeutic agents. J Drug Target. 28:129–141. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Jalalian SH, Ramezani M, Jalalian SA, Abnous K and Taghdisi SM: Exosomes, new biomarkers in early cancer detection. Anal Biochem. 571:1–13. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Makler A and Asghar W: Exosomal biomarkers for cancer diagnosis and patient monitoring. Expert Rev Mol Diagn. 20:387–400. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sedgwick AE and D'Souza-Schorey C: The biology of extracellular microvesicles. Traffic. 19:319–327. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Xu X, Lai Y and Hua ZC: Apoptosis and apoptotic body: Disease message and therapeutic target potentials. Bioscience reports. 39(BSR20180992)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhao D, Tao W, Li S, Chen Y, Sun Y, He Z, Sun B and Sun J: Apoptotic body-mediated intercellular delivery for enhanced drug penetration and whole tumor destruction. Sci Adv. 7(eabg0880)2021.PubMed/NCBI View Article : Google Scholar | |
|
Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Chen J, Chen W and Li Y: Conservation of gene order in human microRNA-neighboring regions. Genome. 55:701–704. 2012.PubMed/NCBI View Article : Google Scholar | |
|
John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human microRNA targets. PLoS Biol. 2(e363)2004.PubMed/NCBI View Article : Google Scholar | |
|
Janas T, Janas MM, Sapoń K and Janas T: Mechanisms of RNA loading into exosomes. FEBS Lett. 589:1391–1398. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, et al: Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: A possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 8:20145–20164. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhang H, Wang Q, Zhao Q and Di W: MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1. J Ovarian Res. 6(84)2013.PubMed/NCBI View Article : Google Scholar | |
|
He L, Zhu W, Chen Q, Yuan Y, Wang Y, Wang J and Wu X: Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics. 9:8206–8220. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Cai J, Gong L, Li G, Guo J, Yi X and Wang Z: Exosomes in ovarian cancer ascites promote epithelial-mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p. Cell Death Dis. 12(210)2021.PubMed/NCBI View Article : Google Scholar | |
|
Lian XY, Zhang H, Liu Q, Lu X, Zhou P, He SQ, Tang RX and Cui J: Ovarian cancer-excreted exosomal miR-199a-5p suppresses tumor metastasis by targeting hypoxia-inducible factor-2α in hypoxia microenvironment. Cancer Commun (Lond). 40:380–385. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cao J, Zhang Y, Mu J, Yang D, Gu X and Zhang J: Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6. Human Cell. 34:1185–1196. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Chen X, Zhou J, Li X and Wang X, Lin Y and Wang X: Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype. Cancer Lett. 435:80–91. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Li W, Zhang X, Wang J, Li M, Cao C, Tan J, Ma D and Gao Q: TGFβ1 in fibroblasts-derived exosomes promotes epithelial-mesenchymal transition of ovarian cancer cells. Oncotarget. 8:96035–96047. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, et al: Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: A role for NKG2D ligands and IL-15Ralpha. PLoS One. 4(e4942)2009.PubMed/NCBI View Article : Google Scholar | |
|
Shen X, Wang C, Zhu H, Wang Y, Wang X, Cheng X, Ge W and Lu W: Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells. J Ovarian Res. 14(38)2021.PubMed/NCBI View Article : Google Scholar | |
|
Alharbi M, Lai A, Guanzon D, Palma C, Zuñiga F, Perrin L, He Y, Hooper JD and Salomon C: Ovarian cancer-derived exosomes promote tumour metastasis in vivo: An effect modulated by the invasiveness capacity of their originating cells. Clin Sci (Lond). 133:1401–1419. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Guan X, Zong ZH, Liu Y, Chen S, Wang LL and Zhao Y: circPUM1 promotes tumorigenesis and progression of ovarian cancer by sponging miR-615-5p and miR-6753-5p. Mol Ther Nucleic Acids. 18:882–892. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zong ZH, Du YP, Guan X, Chen S and Zhao Y: CircWHSC1 promotes ovarian cancer progression by regulating MUC1 and hTERT through sponging miR-145 and miR-1182. J Exp Clin Cancer Res. 38(437)2019.PubMed/NCBI View Article : Google Scholar | |
|
Choi H, Choi Y, Yim HY, Mirzaaghasi A, Yoo JK and Choi C: Biodistribution of exosomes and engineering strategies for targeted delivery of therapeutic exosomes. Tissue Eng Regen Med. 18:499–511. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Y, Bi J, Huang J, Tang Y, Du S and Li P: Exosome: A review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. Int J Nanomedicine. 15:6917–6934. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sharma S, Zuñiga F, Rice GE, Perrin LC, Hooper JD and Salomon C: Tumor-derived exosomes in ovarian cancer-liquid biopsies for early detection and real-time monitoring of cancer progression. Oncotarget. 8:104687–104703. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Rayamajhi S, Nguyen TDT, Marasini R and Aryal S: Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomater. 94:482–494. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xie X, Wu H, Li M, Chen X, Xu X, Ni W, Lu C, Ni R, Bao B and Xiao M: Progress in the application of exosomes as therapeutic vectors in tumor-targeted therapy. Cytotherapy. 21:509–524. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hadla M, Palazzolo S, Corona G, Caligiuri I, Canzonieri V, Toffoli G and Rizzolio F: Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models. Nanomedicine (Lond). 11:2431–2441. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Liu H, Shen M, Zhao D, Ru D, Duan Y, Ding C and Li H: The effect of triptolide-loaded exosomes on the proliferation and apoptosis of human ovarian cancer SKOV3 cells. Biomed Res Int. 2019(2595801)2019.PubMed/NCBI View Article : Google Scholar | |
|
Huang X, Wu W, Jing D, Yang L, Guo H, Wang L, Zhang W, Pu F and Shao Z: Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy. J Control Release. 343:107–117. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si K, Sun B, Chen B and Xiao Z: Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnology. 18(10)2020.PubMed/NCBI View Article : Google Scholar | |
|
Coukos G, Tanyi J and Kandalaft LE: Opportunities in immunotherapy of ovarian cancer. Ann Oncol. 27 (Suppl 1):i11–i15. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al: Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 33:4015–4022. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, et al: Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 10(eaao593)2018.PubMed/NCBI View Article : Google Scholar | |
|
Sangwan K, Sharma V and Goyal PK: Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A review. Curr Mol Med: Jun 22, 2023 (Epub ahead of print). | |
|
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, et al: HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 14:3372–3379. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, Wolinska E, Gaj P, Grazul M, Pilch Z, et al: Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 10(3000)2019.PubMed/NCBI View Article : Google Scholar | |
|
Labani-Motlagh A, Israelsson P, Ottander U, Lundin E, Nagaev I, Nagaeva O, Dehlin E, Baranov V and Mincheva-Nilsson L: Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity. Tumour Biol. 37:5455–5466. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Koh E, Lee EJ, Nam GH, Hong Y, Cho E, Yang Y and Kim IS: Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis. Biomaterials. 121:121–129. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Shimizu A, Sawada K, Kobayashi M, Yamamoto M, Yagi T, Kinose Y, Kodama M, Hashimoto K and Kimura T: Exosomal CD47 plays an essential role in immune evasion in ovarian cancerexosomal CD47 regulates immune evasion in ovarian cancer. Mol Cancer Res. 19:1583–1595. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Qiu Y, Yang Y, Yang R, Liu C, Hsu JM, Jiang Z, Sun L, Wei Y, Li CW, Yu D, et al: Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene. 40:4992–5001. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Tang MK and Wong AS: Exosomes: Emerging biomarkers and targets for ovarian cancer. Cancer Lett. 367:26–33. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Z, Ji M, Wang Q, He N and Li Y: Circular RNA Cdr1as upregulates SCAI to suppress cisplatin resistance in ovarian cancer via miR-1270 suppression. Mol Ther Nucleic Acids. 18:24–33. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 110:13–21. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Cheng L, Wu S, Zhang K, Qing Y and Xu T: A comprehensive overview of exosomes in ovarian cancer: Emerging biomarkers and therapeutic strategies. J Ovarian Res. 10(73)2017.PubMed/NCBI View Article : Google Scholar | |
|
Ryu J and Thomas SN: Quantitative mass spectrometry-based proteomics for biomarker development in ovarian cancer. Molecules. 26(2674)2021.PubMed/NCBI View Article : Google Scholar | |
|
Cortez AJ, Tudrej P, Kujawa KA and Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 81:17–38. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lee EH, Han SE, Park MJ, Kim HJ, Kim HG, Kim CW, Joo BS and Lee KS: Establishment of effective mouse model of premature ovarian failure considering treatment duration of anticancer drugs and natural recovery time. J Menopausal Med. 24:196–203. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Qi Y, Zhu YM and Li B: Comparison of Animal Models for Premature Ovarian Insufficiency Induced by Different Doses of Cyclophosphamide: A Network Meta-analysis, 2022. | |
|
Yang M, Lin L, Sha C, Li T, Zhao D, Wei H, Chen Q, Liu Y, Chen X, Xu W, et al: Bone marrow mesenchymal stem cell-derived exosomal miR-144-5p improves rat ovarian function after chemotherapy-induced ovarian failure by targeting PTEN. Lab Invest. 100:342–352. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sun B, Ma Y, Wang F, Hu L and Sun Y: miR-644-5p carried by bone mesenchymal stem cell-derived exosomes targets regulation of p53 to inhibit ovarian granulosa cell apoptosis. Stem Cell Res Ther. 10(360)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Q, Sun J, Huang Y, Bu S, Guo Y, Gu T, Li B, Wang C and Lai D: Human amniotic epithelial cell-derived exosomes restore ovarian function by transferring microRNAs against apoptosis. Mol Ther Nucleic Acids. 16:407–418. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xiao GY, Cheng CC, Chiang YS, Cheng WT, Liu IH and Wu SC: Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. Sci Rep. 6(23120)2016.PubMed/NCBI View Article : Google Scholar | |
|
Yang W, Zhang J, Xu B, He Y, Liu W and Li J, Zhang S, Lin X, Su D, Wu T and Li J: HucMSC-Derived exosomes mitigate the age-related retardation of fertility in female mice. Mol Ther. 28:1200–1213. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cai JH, Sun YT and Bao S: HucMSCs-exosomes containing miR-21 promoted estrogen production in ovarian granulosa cells via LATS1-mediated phosphorylation of LOXL2 and YAP. Gen Comp Endocrinol. 321(114015)2022.PubMed/NCBI View Article : Google Scholar | |
|
Li H, Huang X, Chang X, Yao J, He Q, Shen Z, Ji Y and Wang K: S100-A9 protein in exosomes derived from follicular fluid promotes inflammation via activation of NF-κB pathway in polycystic ovary syndrome. J Cell Mol Med. 24:114–125. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Y, Pan S, Li Y and Wu X: Exosomal miR-143-3p derived from follicular fluid promotes granulosa cell apoptosis by targeting BMPR1A in polycystic ovary syndrome. Sci Rep. 12(4359)2022.PubMed/NCBI View Article : Google Scholar | |
|
Huang X, Wu B, Chen M, Hong L, Kong P, Wei Z and Teng X: Depletion of exosomal circLDLR in follicle fluid derepresses miR-1294 function and inhibits estradiol production via CYP19A1 in polycystic ovary syndrome. Aging (Albany NY). 12:15414–15435. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Yuan D, Luo J, Sun Y, Hao L, Zheng J and Yang Z: PCOS follicular fluid derived exosomal miR-424-5p induces granulosa cells senescence by targeting CDCA4 expression. Cell Signal. 85(110030)2021.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Y, Tao M, Wei M, Du S, Wang H and Wang X: Mesenchymal stem cells derived exosomal miR-323-3p promotes proliferation and inhibits apoptosis of cumulus cells in polycystic ovary syndrome (PCOS). Artif Cells Nanomed Biotechnol. 47:3804–3813. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Szyposzynska A, Bielawska-Pohl A, Krawczenko A, Doszyn O, Paprocka M and Klimczak A: Suppression of ovarian cancer cell growth by AT-MSC microvesicles. Int J Mol Sci. 21(9143)2020.PubMed/NCBI View Article : Google Scholar | |
|
Guo L, Zhang Y, Wei R, Zhang X, Wang C and Feng M: Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on CCL2/CCR2 signaling axis and promote drug delivery via SNARE-mediated membrane fusion. Theranostics. 10:6581–6598. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Mancilla P, Liberona M, Kato S, Barra J, Gonzalez A and Cuello M: Simvastatin modifies the internalization, endocytic trafficking, and the content of ovarian cancer cellderived extracellular microvesicles which are responsible of inducing migration and invasion in vitro. Int J Gynecol Cancer. 30 (Suppl 3):A192–A193. 2020. | |
|
Kang F, Zhu J, Wu J, Lv T, Xiang H, Tian J, Zhang Y and Huang Z: O2-3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation via nitric oxide-based epigenetic regulation. Chem Sci. 9:6893–6898. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Huang D, Chen J, Yang C and Wang M: TPX2 silencing mediated by joint action of microvesicles and ultrasonic radiation inhibits the migration and invasion of SKOV3 cells. Mol Med Rep. 17:7627–7635. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yang Z, Du X, Wang C, Zhang J, Liu C, Li Y and Jiang H: Therapeutic effects of human umbilical cord mesenchymal stem cell-derived microvesicles on premature ovarian insufficiency in mice. Stem Cell Res Ther. 10(250)2019.PubMed/NCBI View Article : Google Scholar | |
|
Faruk EM: El desoky RE, El-Shazly AM and Taha NM: Does exosomes derived bone marrow mesenchymal stem cells restore ovarian function by promoting stem cell survival on experimentally induced polycystic ovary in adult female albino rats?(Histological and Immunohistochemical Study). J Stem Cell Res Ther. 8(1000442)2018. | |
|
Zweemer AJM, French CB, Mesfin J, Gordonov S, Meyer AS and Lauffenburger DA: Apoptotic bodies Elicit Gas6-mediated migration of AXL-Expressing tumor cell. Mol Cancer Res. 15:1656–1666. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL and Holmgren L: Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA. 98:6407–6411. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Muhsin-Sharafaldine MR, Kennedy BR, Saunderson SC, Buchanan CR, Dunn AC, Faed JM and McLellan AD: Mechanistic insight into the procoagulant activity of tumor-derived apoptotic vesicles. Biochim Biophys Acta Gen Subj. 1861:286–295. 2017.PubMed/NCBI View Article : Google Scholar |
